Peptides.info

Anti-inflammatory tripeptide

KPV

Preclinical

Also known as α-MSH (11-13)

The three-residue tail of α-MSH that calms inflammation.

Cited sources
2
Human-tested claims
0 of 3
Best evidence
Tier 3 · Preclinical
Status
Research-only

A tripeptide from the tail end of alpha-MSH, studied for anti-inflammatory activity in the gut and skin. Its mechanism appears to run largely independent of melanocortin receptors; the preclinical data are real, but human trials are absent.

anti-inflammatorygutinvestigational

How it works

Despite coming from α-MSH, KPV's anti-inflammatory effect looks receptor-independent: it is taken into cells by the PepT1 transporter and dampens NF-κB and related inflammatory signaling from the inside, rather than acting as a melanocortin-receptor agonist.

Sequence: KPVThe C-terminal tripeptide of α-MSH (residues 11–13).

What it's studied for

One claim per card, each with its own tier and source. Tiers 1 and 2 are human data. Tiers 3 and 4 are not yet.

Regulatory & legal status

Research-only

Not approved for human use anywhere; research-only. Low production cost has driven grey-market availability well ahead of any clinical validation.

[1]Dalmasso et al., 2008 (Gastroenterology)(opens in a new tab)

Frequently asked

Does KPV work through the melanocortin receptors like α-MSH?

Evidence suggests mostly not — its anti-inflammatory action appears to be receptor-independent, via cellular uptake and NF-κB inhibition. All of this is preclinical so far.

References

  1. [1]Dalmasso et al., 2008 (Gastroenterology) (opens in a new tab)
  2. [2]Getting et al., 2003 (dissecting α-MSH, PubMed) (opens in a new tab)

Written by Twenty Residues editorial. Medical review: pending; a named reviewer is being assigned.

Last updated September 19, 2026.

Spot an error or a better source? Report a correction. Every change is logged below.

Update history
  • 2026-09-19 — Sourced review — every claim checked against primary literature; sequence, regulatory status, safety, and FAQs added.